BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...CSO of CCRM. Both are professors at the University of Toronto; Zandstra is also a University of British Columbia...
BioCentury | May 1, 2020
Distillery Therapeutics

Thioredoxin reducing enzyme inhibitors for solid tumors

...Adv. ; published online March 20, 2020 doi:10.1126/sciadv.aax7945 CONTACT: Brent Page, Karolinska Institute, Stockholm, Sweden; University of British Columbia...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

...replication of SARS-CoV-2 by over 1,000-fold. The study , from the Karolinska Institutet and the University of British Columbia...
BioCentury | Jan 9, 2020
Financial News

Aspect to engineer therapeutic tissues with $20M series A

...A round to develop the engineered tissues as therapeutics. New investor Radical Ventures led the University of British Columbia...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...Pharmaceuticals Inc. (NASDAQ:XFOR). Camp4 also appointed Michael Hayden, a professor of medical genetics at the University of British Columbia...
BioCentury | Sep 19, 2019
Translation in Brief

Public funding highlights

...investigator at National Cancer Institute , was named chair in Precision Cancer Drug Design at University of British Columbia...
BioCentury | Aug 30, 2019
Translation in Brief

DNA trumps protein in Huntington onset

...as most important," said AJHG study coauthor Hayden, who is director and senior scientist at University of British Columbia's...
...1; MSH3 - MutS Homolog 3 Karen Tkach Tuzman, Associate Editor Harvard Medical School Massachusetts General Hospital Triplet Therapeutics Inc. University of British Columbia Huntingtin...
BioCentury | Aug 29, 2019
Distillery Techniques

Counting uninterrupted CAG triplets in HTT gene to predict age of onset for Huntington disease

...sequences in HTT could help predict age of onset for HD. In patients from the University of British Columbia...
...genes that control the maintenance of DNA stability. Next steps by Michael Hayden's lab at University of British Columbia...
...2019 doi: 10.1016/j.ajhg.2019.04.007 CONTACT: Michael R. Hayden, University of British Columbia, Vancouver, B.C. e-mail: mrh@cmmt.ubc.ca Karen Tkach Tuzman Harvard Medical School University of British Columbia Huntington...
BioCentury | Jul 12, 2019
Preclinical News

July 12 Preclinical Quick Takes: Feng Zhang develops latest RNA editing platform, plus tools from David Liu and NIH

...could help improve gene editing A team from NCI, University of Illinois at Chicago and University of British Columbia...
...Mary Romeo, Assistant Editor Broad Institute of MIT and Harvard Harvard University Massachusetts Institute of Technology National Institutes of Health University of British Columbia University...
BioCentury | Feb 12, 2019
Translation in Brief

Stabilizing mutant proteins

...A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy...
...κ light polypeptide gene enhancer in B cells 1 Sandi Wong, Staff Writer NIBR Novartis Institutes for BioMedical Research University of British Columbia Mucosa...
Items per page:
1 - 10 of 210
BioCentury | Feb 10, 2021
Finance

Notch’s $85M series A builds on Allogene deal for off-the-shelf, iPSC-derived cell therapies

...CSO of CCRM. Both are professors at the University of Toronto; Zandstra is also a University of British Columbia...
BioCentury | May 1, 2020
Distillery Therapeutics

Thioredoxin reducing enzyme inhibitors for solid tumors

...Adv. ; published online March 20, 2020 doi:10.1126/sciadv.aax7945 CONTACT: Brent Page, Karolinska Institute, Stockholm, Sweden; University of British Columbia...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

...replication of SARS-CoV-2 by over 1,000-fold. The study , from the Karolinska Institutet and the University of British Columbia...
BioCentury | Jan 9, 2020
Financial News

Aspect to engineer therapeutic tissues with $20M series A

...A round to develop the engineered tissues as therapeutics. New investor Radical Ventures led the University of British Columbia...
BioCentury | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

...Pharmaceuticals Inc. (NASDAQ:XFOR). Camp4 also appointed Michael Hayden, a professor of medical genetics at the University of British Columbia...
BioCentury | Sep 19, 2019
Translation in Brief

Public funding highlights

...investigator at National Cancer Institute , was named chair in Precision Cancer Drug Design at University of British Columbia...
BioCentury | Aug 30, 2019
Translation in Brief

DNA trumps protein in Huntington onset

...as most important," said AJHG study coauthor Hayden, who is director and senior scientist at University of British Columbia's...
...1; MSH3 - MutS Homolog 3 Karen Tkach Tuzman, Associate Editor Harvard Medical School Massachusetts General Hospital Triplet Therapeutics Inc. University of British Columbia Huntingtin...
BioCentury | Aug 29, 2019
Distillery Techniques

Counting uninterrupted CAG triplets in HTT gene to predict age of onset for Huntington disease

...sequences in HTT could help predict age of onset for HD. In patients from the University of British Columbia...
...genes that control the maintenance of DNA stability. Next steps by Michael Hayden's lab at University of British Columbia...
...2019 doi: 10.1016/j.ajhg.2019.04.007 CONTACT: Michael R. Hayden, University of British Columbia, Vancouver, B.C. e-mail: mrh@cmmt.ubc.ca Karen Tkach Tuzman Harvard Medical School University of British Columbia Huntington...
BioCentury | Jul 12, 2019
Preclinical News

July 12 Preclinical Quick Takes: Feng Zhang develops latest RNA editing platform, plus tools from David Liu and NIH

...could help improve gene editing A team from NCI, University of Illinois at Chicago and University of British Columbia...
...Mary Romeo, Assistant Editor Broad Institute of MIT and Harvard Harvard University Massachusetts Institute of Technology National Institutes of Health University of British Columbia University...
BioCentury | Feb 12, 2019
Translation in Brief

Stabilizing mutant proteins

...A team from Novartis Institutes for BioMedical Research (NIBR) and University of British Columbia has hit upon a strategy...
...κ light polypeptide gene enhancer in B cells 1 Sandi Wong, Staff Writer NIBR Novartis Institutes for BioMedical Research University of British Columbia Mucosa...
Items per page:
1 - 10 of 210